2-(α-hydroxyacetyl)pyridine | 95836-52-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(α-hydroxyacetyl)pyridine
• 英文别名: 2-(2-hydroxyacetyl)pyridine；2-Hydroxyacetylpyridine；2-hydroxy-1-[2]pyridyl-ethanone；2-Hydroxy-1-[2]pyridyl-aethanon；2-Hydroxy-1-(2-pyridyl)ethanone；2-hydroxy-1-pyridin-2-ylethanone
• CAS: 95836-52-5
• 化学式: C₇H₇NO₂
• 分子量: 137.138
• InChiKey: BQQLUQRZQOODGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(α-hydroxyacetyl)pyridine 在 一水合肼 作用下， 以 甲醇 为溶剂， 反应 3.5h， 以54%的产率得到2-hydrazinylidene-2-pyridin-2-ylethanol
  参考文献：
  名称：

  2-乙酰基吡啶硫代半氨基甲酮XI：2-（α-羟基乙酰基）吡啶硫代氨基甲酮类作为抗疟和抗菌剂。

  摘要：

  合成了一系列的2-（α-羟基乙酰基）吡啶硫代氨基甲唑酮作为潜在的抗疟和抗菌剂。它们的合成通过N4-单-或N4，N4-二取代的硫代氨基脲与2-（α-羟基乙酰基）吡啶的缩合而实现。后者通过选择性溴氧化（2-吡啶基）-1，2-乙二醇来制备。新化合物对青霉素敏感和耐青霉素的淋病奈瑟菌（MIC，0.5-0.004微克/ mL），脑膜炎奈瑟菌（MIC，0.5-0.032微克/ mL）和金黄色葡萄球菌（MIC， 0.5-2毫克/毫升）。在这些新药中，大多数对恶性疟原虫（史密斯菌株； ID50，6.7-38 ng / mL）具有良好的体外抗疟作用，但是12种化合物中只有3种对伯氏疟原虫表现出中等的体内活性。与相应的2-乙酰基吡啶硫代半氨基甲酮相比，这些新剂对宿主的毒性较小，水溶性更高。

  DOI：

  10.1002/jps.2600731226
• 作为产物：
  描述：

  2-氧代-2-(吡啶-2-基)乙酸乙酯 在 盐酸 、 水 、 碳酸氢钠 作用下， 以 水 为溶剂， 反应 1.5h， 生成 2-(α-hydroxyacetyl)pyridine
  参考文献：
  名称：

  Structure–activity relationships of 2-aminothiazoles effective against Mycobacterium tuberculosis

  摘要：

  A series of 2-aminothiazoles was synthesized based on a HTS scaffold from a whole-cell screen against Mycobacterium tuberculosis (Mtb). The SAR shows the central thiazole moiety and the 2-pyridyl moiety at C-4 of the thiazole are intolerant to modification. However, the N-2 position of the aminothiazole exhibits high flexibility and we successfully improved the antitubercular activity of the initial hit by more than 128-fold through introduction of substituted benzoyl groups at this position. N-(3-Chlorobenzoyl)-4-(2-pyridinyl)-1,3-thiazol-2-amine (55) emerged as one of the most promising analogues with a MIC of 0.024 mu M or 0.008 mu g/mL in 7H9 media and therapeutic index of nearly similar to 300. However, 55 is rapidly metabolized by human liver microsomes (t(1/2) = 28 min) with metabolism occurring at the invariant aminothiazole moiety and Mtb develops spontaneous low-level resistance with a frequency of similar to 10 (5). (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.08.048

文献信息

• [EN] METHOD FOR PRODUCING ALPHA-KETOALDEHYDE COMPOUND<br/>[FR] PROCÉDÉ DE PRODUCTION D'UN COMPOSÉ D'ALPHA-CÉTOALDÉHYDE
  申请人：SUMITOMO CHEMICAL CO

  公开号：WO2013018626A1

  公开（公告）日：2013-02-07

  An object of the present invention is to provide a new method for producing an ALPHA-ketoaldehyde compound from a 2-oxo-primary alcohol compound. The present invention provides a method for producing an ALPHA-ketoaldehyde compound including a step of oxidizing a 2-oxo-primary alcohol compound in the presence of platinum, a platinum compound, iron or an iron compound. The 2-oxo-primary alcohol compound is preferably a compound represented by the formula (1a), and the ALPHA-ketoaldehyde compound is preferably a compound represented by the formula (2a), wherein Ra is a C1-C6 alkyl group which may have a substituent or a C6-C20 aryl group which may have a substituent.

  本发明的一个目的是提供一种从2-氧代初级醇化合物制备ALPHA-酮醛化合物的新方法。本发明提供了一种制备ALPHA-酮醛化合物的方法，包括在铂、铂化合物、铁或铁化合物存在下氧化2-氧代初级醇化合物的步骤。2-氧代初级醇化合物最好是由式（1a）表示的化合物，而ALPHA-酮醛化合物最好是由式（2a）表示的化合物，其中Ra是一个可能带有取代基的C1-C6烷基基团或可能带有取代基的C6-C20芳基基团。
• Thienopyrrole compound and use thereof as HCV polymerase inhibitor
  申请人：Mizojiri Ryo

  公开号：US20060167246A1

  公开（公告）日：2006-07-27

  The present invention relates to a thienopyrrole compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound as an active ingredient. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由下式[I]所表示的噻吡咯烷化合物，其中每个符号如规范中定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和含有该化合物作为活性成分的治疗剂。本发明的化合物基于HCV聚合酶抑制活性显示抗HCV活性，并且可用作丙型肝炎的预防或治疗剂。
• Hypervalent Iodine Oxidation of Enol Silyl Ethers using Boron Trifluoride Etherate. A Direct Route to Aryl Hydroxymethyl Ketones
  作者：Robert M. Moriarty、Om Prakash、Michael P. Duncan

  DOI：10.1055/s-1985-31394

  日期：——

  Enol silyl ethers of acetophenones and acetylpyridines are oxidized to hydroxymethyl aryl ketones (ω-hydroxyacetophenones) and hydroxyacetylpyridines, respectively, using the system iodosobenzene/boron trifluoride etherate/water.

  使用碘代苯/三氟化硼乙醚/水体系，将乙酰苯和乙酰吡啶的烯丙基硅醚分别氧化为羟甲基芳基酮（β-羟基苯乙酮）和羟基乙酰吡啶。
• 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Mizojiri Ryo

  公开号：US20090036444A1

  公开（公告）日：2009-02-05

  The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]表示的融合环化合物，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物基于HCV聚合酶抑制活性具有抗HCV活性，是一种预防或治疗丙型肝炎的药剂。
• Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Oka Takahiro

  公开号：US20070049593A1

  公开（公告）日：2007-03-01

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其化学式为[I]，其中每个符号的定义如规范中所述，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物表现出基于HCV聚合酶抑制活性的抗HCV活性，因此可用作预防或治疗丙型肝炎的药物。